Changes in gene expression induced by Sp1 knockdown differ from those caused by challenging Sp1 binding to gene promoters - PubMed (original) (raw)
. 2011 Jul;1809(7):327-36.
doi: 10.1016/j.bbagrm.2011.06.003. Epub 2011 Jun 13.
Affiliations
- PMID: 21684359
- DOI: 10.1016/j.bbagrm.2011.06.003
Changes in gene expression induced by Sp1 knockdown differ from those caused by challenging Sp1 binding to gene promoters
Sylvia Mansilla et al. Biochim Biophys Acta. 2011 Jul.
Abstract
C/G-rich DNA regions, which include those recognized by the Sp1 transcription factor in several gene promoters, also encompass potential binding sites for the DNA-intercalating anthracyclines doxorubicin and WP631. We explored the differences between changes in gene expression caused by the ability of these drugs to compete with Sp1 for binding to DNA and those produced by Sp1 knockdown. By quantitative RT-PCR of around 100 genes, most of them involved in control of cell cycle progression, we found that the treatment of human MDA-MB231 breast carcinoma cells with bis-anthracycline WP631 for 24 h produced a profile of gene down-regulation markedly different from the profile caused by doxorubicin treatment or by stable Sp1 knockdown. These observations are rationalized by considering a near-specific effect of WP631 on Sp1 interaction with several gene promoters, thus representing potential therapeutic targets for WP631, in contrast to a less specific effect of reducing the availability of Sp1 through RNA interference. Genes down-regulated upon each treatment were mapped to their molecular and biological functions, which documented the down-regulation, among other things, of genes involved in mRNA transcription regulation, granting us insights into the effects of challenging the transactivation of gene expression by Sp1.
Copyright © 2011 Elsevier B.V. All rights reserved.
Similar articles
- Analysis of the effects of daunorubicin and WP631 on transcription.
Portugal J, Martín B, Vaquero A, Ferrer N, Villamarín S, Priebe W. Portugal J, et al. Curr Med Chem. 2001 Jan;8(1):1-8. doi: 10.2174/0929867013373976. Curr Med Chem. 2001. PMID: 11172687 Review. - Sp1 transcription factor as a target for anthracyclines: effects on gene transcription.
Mansilla S, Portugal J. Mansilla S, et al. Biochimie. 2008 Jul;90(7):976-87. doi: 10.1016/j.biochi.2007.12.008. Epub 2008 Jan 5. Biochimie. 2008. PMID: 18226599 Review. - Sp1-targeted inhibition of gene transcription by WP631 in transfected lymphocytes.
Mansilla S, Priebe W, Portugal J. Mansilla S, et al. Biochemistry. 2004 Jun 15;43(23):7584-92. doi: 10.1021/bi036185e. Biochemistry. 2004. PMID: 15182200 - Bisanthracycline WP631 inhibits basal and Sp1-activated transcription initiation in vitro.
Martín B, Vaquero A, Priebe W, Portugal J. Martín B, et al. Nucleic Acids Res. 1999 Sep 1;27(17):3402-9. doi: 10.1093/nar/27.17.3402. Nucleic Acids Res. 1999. PMID: 10446226 Free PMC article.
Cited by
- Epigenomics of human CD8 T cell differentiation and aging.
Moskowitz DM, Zhang DW, Hu B, Le Saux S, Yanes RE, Ye Z, Buenrostro JD, Weyand CM, Greenleaf WJ, Goronzy JJ. Moskowitz DM, et al. Sci Immunol. 2017 Feb;2(8):eaag0192. doi: 10.1126/sciimmunol.aag0192. Epub 2017 Feb 17. Sci Immunol. 2017. PMID: 28439570 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous